Pioneering Specialty Pharma Chooses TrialMaster Electronic Data Capture
Fort Lauderdale, FL, April 7, 2014 –- A leading US specialty pharmaceutical company focused on the development and commercialization of novel medicines has selected OmniComm Systems, Inc.’s (OTCQB: OMCM), TrialMaster for three clinical studies comprising a Phase II, Phase III, and safety and pharmacokinetic study.
A pioneer in the field of novel therapies, this specialty pharma’s choice of OmniComm’s technology reflects their commitment to best-in-class EDC technology in its development of therapies to prevent and treat a wide range of disease states.
Due to the unique nature of their research, the company specifically sought technology that would be easy to learn and intuitive to use for clinicians participating in these clinical studies. Through TrialMaster, their researchers will use a single interface for data capture, data management and reporting. TrialMaster also includes embedded eLearning, allowing their clinicians to easily learn the system and initiate trials quickly.
The company also selected IVR Clinical Concepts (IVRCC) secure Interactive Voice and Interactive Web Response applications (IVR/IWR) that interfaces seamlessly with TrialMaster for efficient patient recruitment and randomization.
“TrialMaster’s open architecture offers a quick and easy, configurable method for data consolidation and integration with best-in-class systems such as IVRCC’s IWR technology. The market has realized that OmniComm is the specialist in EDC technologies” said Dr Kuno van der Post, SVP business development. “We’re excited to work with this leading specialty pharmaceutical company to help them tap into the power of TrialMaster to support the development of their pioneering therapies.”
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.